The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prospective evaluation of a developed S-1 dosage formula based on renal function.
 
Takuro Mizukami
Consulting or Advisory Role - Merck Serono
Speakers' Bureau - Otsuka; Taiho Pharmaceutical; Teijin Pharma
 
Masashi Takeuchi
No Relationships to Disclose
 
Chiyo K. Imamura
Employment - Amgen (I); Gilead Sciences (I)
Honoraria - Chugai Pharma
Consulting or Advisory Role - Ono Pharmaceutical
 
Eisuke Booka
No Relationships to Disclose
 
HIROYA TAKEUCHI
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Lilly; EA Pharma; Ethicon; Japan Blood Products Organization; Kaken Pharmaceutical; Lilly Japan; Medicon; Medtronic; Merck Serono; Nippon Kayaku; Otsuka; Pfizer; Sanofi; Taiho Pharmaceutical; Tsumura & Co.
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Japan Blood Products Organization (Inst); Lilly Japan (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Takeshi Kawakami
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda
 
Taro Funakoshi
No Relationships to Disclose
 
Kazushige Wakuda
Honoraria - Boehringer Ingelheim; Taiho Pharmaceutical
 
Yu Aoki
No Relationships to Disclose
 
Yasuo Hamamoto
No Relationships to Disclose
 
Minoru Kitago
No Relationships to Disclose
 
Hirofumi Kawakubo
No Relationships to Disclose
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Yusuke Tanigawara
Speakers' Bureau - Chugai Pharma
Research Funding - Taiho Pharmaceutical
 
Yuko Kitagawa
Honoraria - Asahi Kasei; Chugai Pharma; Ethicon; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ajinomoto (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); EA Pharma (Inst); GlaxoSmithKline (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kureha (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Medicon (Inst); Medtronic (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Taisho Toyama Pharma (Inst); Takeda (Inst); Teijin Pharma (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)